Loading
The first frontline regimen to beat R-CHOP in high-risk large B-cell lymphoma since rituximab, by adding a CD19 antibody and lenalidomide.
frontMIND, trial NCT04824092 sponsored by Incyte and MorphoSys and published in the Lancet in 2026, produced the first frontline regimen to beat R-CHOP in high-risk large B-cell lymphoma since rituximab itself, by adding the CD19 antibody tafasitamab and lenalidomide. It randomised 899 patients with IPI 3 to 5 disease to tafasitamab plus lenalidomide with R-CHOP or placebo with R-CHOP and met its primary progression-free survival endpoint at two years after a median follow-up of 35.2 months, with overall survival immature and added haematological toxicity; a supplemental application was planned for the first half of 2026. OnCo links it to lymphoma, tafasitamab, lenalidomide and the IPI term. Whether the progression benefit converts into a survival benefit, and how the regimen compares with Pola-R-CHP, are the open questions.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Tafasitamab, Incyte, Lenalidomide, Monoclonal antibodies.
Shares Tafasitamab, Incyte, Lenalidomide, Monoclonal antibodies.
Shares Tafasitamab, Incyte, Lenalidomide, Monoclonal antibodies.
Shares Tafasitamab, Incyte, Monoclonal antibodies.
Shares Tafasitamab, Lenalidomide, Monoclonal antibodies, Diffuse large B-cell lymphoma.
Shares Tafasitamab, Incyte, Lenalidomide, Monoclonal antibodies.
Shares Tafasitamab, Incyte, Lenalidomide, Monoclonal antibodies.
Shares Tafasitamab, Monoclonal antibodies, Diffuse large B-cell lymphoma.